Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs.
Porta, Chiara
Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. [electronic resource] - Cancer research 07 2020 - 2874-2888 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1538-7445
10.1158/0008-5472.CAN-19-2843 doi
Animals
Apoptosis
Cell Differentiation
Cell Proliferation
Colorectal Neoplasms--drug therapy
Dinoprostone--pharmacology
Humans
Immune Tolerance
Interferon-gamma--metabolism
Melanoma, Experimental--drug therapy
Mice
Monocytes--drug effects
Myeloid-Derived Suppressor Cells--drug effects
NF-kappa B p50 Subunit--genetics
Nitric Oxide--metabolism
Oxytocics--pharmacology
Pancreatic Neoplasms--drug therapy
Tumor Cells, Cultured
Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. [electronic resource] - Cancer research 07 2020 - 2874-2888 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1538-7445
10.1158/0008-5472.CAN-19-2843 doi
Animals
Apoptosis
Cell Differentiation
Cell Proliferation
Colorectal Neoplasms--drug therapy
Dinoprostone--pharmacology
Humans
Immune Tolerance
Interferon-gamma--metabolism
Melanoma, Experimental--drug therapy
Mice
Monocytes--drug effects
Myeloid-Derived Suppressor Cells--drug effects
NF-kappa B p50 Subunit--genetics
Nitric Oxide--metabolism
Oxytocics--pharmacology
Pancreatic Neoplasms--drug therapy
Tumor Cells, Cultured